NVS : Summary for Novartis AG Common Stock - Yahoo Finance

U.S. Markets close in 3 hrs 36 mins

Novartis AG (NVS)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
76.96-0.10 (-0.13%)
As of 12:23PM EDT. Market open.
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close77.06
Bid0.00 x
Ask0.00 x
Day's Range76.60 - 76.98
52 Week Range66.93 - 83.58
Avg. Volume2,701,635
Market Cap181.79B
PE Ratio (TTM)27.49
Earnings DateN/A
Dividend & Yield2.72 (3.69%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Financial Times23 minutes ago

    [$$] Biotech and big pharma reap rewards from partnerships

    Biotech can easily get overshadowed by its larger and more profit-generating cousin, big pharma. However, the symbiosis between the two sectors has never been greater. Previously the small companies, usually ...

  • Novartis AG :NVS-US: Earnings Analysis: Q1, 2017 By the Numbers : April 28, 2017
    Capital Cube1 hour ago

    Novartis AG :NVS-US: Earnings Analysis: Q1, 2017 By the Numbers : April 28, 2017

    Categories: Yahoo FinanceGet free summary analysis Novartis AG reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Novartis AG – Johnson & Johnson, GlaxoSmithKline plc Sponsored ADR and Abbott Laboratories (JNJ-US, GSK-US and ABT-US) that have also reported for this period. Highlights Summary numbers: Revenues of ... Read more (Read more...)

  • Reuters2 hours ago

    U.S. FDA approves Novartis' leukemia treatment

    The U.S. Food and Drug Administration approved Novartis AG's Rydapt as an initial treatment for acute myeloid leukemia (AML) as well as certain other blood disorders, the agency said on Friday. AML is a cancer that forms in the bone marrow and progresses rapidly, resulting in an abnormal increase in white blood cells. Rydapt is approved to be used along with chemotherapy to treat adults newly diagnosed with AML and carrying a specific genetic mutation called FLT3, the FDA said.